Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORATACE: Sorafenib as inhibitor of collateral tumor vessel growth during TACE for hepatocellular carcinoma
2008-000601-11Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Medical University of Vienna. Started Apr 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-000601-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000601-11.